Dr. Benjamin A. Bogucki, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 688
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Ohio State University College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
OH license 35121262 · MO license 2009009411
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Integrated Dermatology of Columbus LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 688
- Services billed
- 4,327
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,669 | 266 |
| Established patient office or other outpatient visit, 20-29 minutes | 663 | 465 |
| Destruction of precancer skin growth, 1 growth | 482 | 337 |
| Biopsy of related skin growth, first growth | 244 | 207 |
| Destruction of skin growth, 1-14 growths | 207 | 180 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 149 | 120 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 120 | 91 |
| Established patient office or other outpatient visit, 30-39 minutes | 97 | 73 |
| New patient office or other outpatient visit, 30-44 minutes | 82 | 82 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 57 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Doxycycline Hyclate Other prescribers in Columbus, OH | 213 |
| Triamcinolone Acetonide Other prescribers in Columbus, OH | 204 |
| Ketoconazole Other prescribers in Columbus, OH | 140 |
| Hydrocortisone Other prescribers in Columbus, OH | 134 |
| Fluocinonide Other prescribers in Columbus, OH | 74 |
| Clobetasol Propionate Other prescribers in Columbus, OH | 61 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 60 |
| Mupirocin Other prescribers in Columbus, OH | 45 |
| Metronidazole Other prescribers in Columbus, OH | 31 |
| Fluorouracil Other prescribers in Columbus, OH | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 213 payments worth $3,393 in total to this clinician.
| AbbVie Inc. | $640 |
|---|---|
| Leo Pharma Inc. | $371 |
| UCB, Inc. | $337 |
| Pfizer Inc. | $304 |
| Janssen Biotech, Inc. | $293 |
| Genzyme Corporation | $257 |
| Arcutis Biotherapeutics, Inc. | $214 |
| E.r. Squibb & Sons, L.l.c. | $194 |
| Food and Beverage | $3,281 |
|---|---|
| Education | $112 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 28, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Janssen Pharmaceuticals, Inc Dec 5, 2025 | Education TREMFYA · Immunology · in-kind | $13.17 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $253,570 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Incyte Corporation - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie Inc. · Active, not recruiting · NCT06118411 - M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (St…
AbbVie Inc. - A phase 2 multicenter randomized doubleblind placebocontrolled 16WEEK study evaluating the safety and efficacy of ritlecitinib PF06651600 in adults with moderate to severe hidradenitis suppurativa
Pfizer Inc. - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)
AbbVie Inc. - Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT04036435 - A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis …
Amgen Inc. - M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc. - Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Sanofi US Services Inc. · Completed · NCT04781816
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.